Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
Sinar Daily on MSN1h
Seven-year trial shows 48 per cent survival with dual immunotherapyPatients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.
Methods Prospective analysis on all consecutive patients who underwent neoadjuvant chemotherapy and nivolumab followed by surgery (March 2023-April 2024), in a single centre. Indication for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback